April 20, 2026 · Form 4 insider transaction
BROADWOOD PARTNERS, L.P. bought 0 shares of Insight Molecular Diagnostics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.
The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.